Vir Biotechnology Shares Fall After $150 Million Stock Offering is Priced

Dow Jones11-13

Shares of Vir Biotechnology fell after the company announced the pricing of its $150 million underwritten public offering.

The stock sank 13% in premarket trading Friday. Through Thursday's close, shares have roughly doubled in value year to date.

The biopharmaceutical company late Thursday said it will sell 15 million shares of its common stock to the public for $10 a share, resulting in gross proceeds of about $150 million before deducting underwriting costs, commissions and offering expenses.

Vir Biotechnology also granted underwriters a 30-day option to purchase up to an additional 2.25 million shares of its common stock at the public offering price, minus underwriting discounts and commissions.

Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers for the offering, which is expected to close Monday.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment